Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

4,6-Diaminopyrimidines as Highly Preferred Troponin I-Interacting Kinase (TNNI3K) Inhibitors.

Philp J, Lawhorn BG, Graves AP, Shewchuk L, Rivera KL, Jolivette LJ, Holt DA, Gatto GJ Jr, Kallander LS.

J Med Chem. 2018 Apr 12;61(7):3076-3088. doi: 10.1021/acs.jmedchem.8b00125. Epub 2018 Mar 21.

PMID:
29561151
2.

Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.

Qin P, Arabacilar P, Bernard RE, Bao W, Olzinski AR, Guo Y, Lal H, Eisennagel SH, Platchek MC, Xie W, Del Rosario J, Nayal M, Lu Q, Roethke T, Schnackenberg CG, Wright F, Quaile MP, Halsey WS, Hughes AM, Sathe GM, Livi GP, Kirkpatrick RB, Qu XA, Rajpal DK, Faelth Savitski M, Bantscheff M, Joberty G, Bergamini G, Force TL, Gatto GJ Jr, Hu E, Willette RN.

J Am Heart Assoc. 2017 May 9;6(5). pii: e004453. doi: 10.1161/JAHA.116.004453.

3.

Substituent Effects on Drug-Receptor H-bond Interactions: Correlations Useful for the Design of Kinase Inhibitors.

Lawhorn BG, Philp J, Graves AP, Holt DA, Gatto GJ Jr, Kallander LS.

J Med Chem. 2016 Dec 8;59(23):10629-10641. Epub 2016 Nov 22.

PMID:
27933961
4.

GSK114: A selective inhibitor for elucidating the biological role of TNNI3K.

Lawhorn BG, Philp J, Graves AP, Shewchuk L, Holt DA, Gatto GJ Jr, Kallander LS.

Bioorg Med Chem Lett. 2016 Jul 15;26(14):3355-3358. doi: 10.1016/j.bmcl.2016.05.033. Epub 2016 May 14.

PMID:
27246618
5.

Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K).

Lawhorn BG, Philp J, Zhao Y, Louer C, Hammond M, Cheung M, Fries H, Graves AP, Shewchuk L, Wang L, Cottom JE, Qi H, Zhao H, Totoritis R, Zhang G, Schwartz B, Li H, Sweitzer S, Holt DA, Gatto GJ Jr, Kallander LS.

J Med Chem. 2015 Sep 24;58(18):7431-48. doi: 10.1021/acs.jmedchem.5b00931. Epub 2015 Sep 10.

PMID:
26355916
6.

Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart.

Vagnozzi RJ, Gatto GJ Jr, Kallander LS, Hoffman NE, Mallilankaraman K, Ballard VL, Lawhorn BG, Stoy P, Philp J, Graves AP, Naito Y, Lepore JJ, Gao E, Madesh M, Force T.

Sci Transl Med. 2013 Oct 16;5(207):207ra141. doi: 10.1126/scitranslmed.3006479.

7.

Novel nicotinic acetylcholine receptor agonists containing carbonyl moiety as a hydrogen bond acceptor.

Mazurov AA, Kombo DC, Akireddy S, Murthy S, Hauser TA, Jordan KG, Gatto GJ, Yohannes D.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3927-34. doi: 10.1016/j.bmcl.2013.04.058. Epub 2013 May 1.

PMID:
23692872
8.

Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor.

Arias HR, Fedorov NB, Benson LC, Lippiello PM, Gatto GJ, Feuerbach D, Ortells MO.

J Pharmacol Exp Ther. 2013 Jan;344(1):113-23. doi: 10.1124/jpet.112.197905. Epub 2012 Sep 25.

PMID:
23010362
9.

Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders.

Mazurov AA, Miao L, Bhatti BS, Strachan JP, Akireddy S, Murthy S, Kombo D, Xiao YD, Hammond P, Zhang J, Hauser TA, Jordan KG, Miller CH, Speake JD, Gatto GJ, Yohannes D.

J Med Chem. 2012 Nov 8;55(21):9181-94. doi: 10.1021/jm3006542. Epub 2012 Jul 27.

PMID:
22793665
10.

Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats.

Rezvani AH, Cauley MC, Johnson EC, Gatto GJ, Levin ED.

Psychopharmacology (Berl). 2012 Oct;223(3):251-8. doi: 10.1007/s00213-012-2712-2. Epub 2012 Apr 20.

PMID:
22526540
11.

NADPH oxidase-dependent and -independent mechanisms of reported inhibitors of reactive oxygen generation.

Gatto GJ Jr, Ao Z, Kearse MG, Zhou M, Morales CR, Daniels E, Bradley BT, Goserud MT, Goodman KB, Douglas SA, Harpel MR, Johns DG.

J Enzyme Inhib Med Chem. 2013 Feb;28(1):95-104. doi: 10.3109/14756366.2011.636360. Epub 2011 Dec 3.

PMID:
22136506
12.

Development of a high-throughput cell-based assay for superoxide production in HL-60 cells.

Seitz PM, Cooper R, Gatto GJ Jr, Ramon F, Sweitzer TD, Johns DG, Davenport EA, Ames RS, Kallal LA.

J Biomol Screen. 2010 Apr;15(4):388-97. doi: 10.1177/1087057109359687. Epub 2010 Mar 12.

PMID:
20228280
13.

TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.

Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA, Stachowiak EK, Stachowiak MK, Papke RL, Lippiello PM, Bencherif M.

Biochem Pharmacol. 2009 Oct 1;78(7):803-12. doi: 10.1016/j.bcp.2009.05.030. Epub 2009 May 29.

14.

TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.

Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, Xie J, Bencherif M.

CNS Neurosci Ther. 2008 Winter;14(4):266-77. doi: 10.1111/j.1755-5949.2008.00054.x. Review.

15.

Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties.

Lippiello P, Letchworth SR, Gatto GJ, Traina VM, Bencherif M.

J Mol Neurosci. 2006;30(1-2):19-20.

PMID:
17192610
16.

Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine receptors.

Bencherif M, Hauser TA, Jordan KG, Gatto GJ.

J Mol Neurosci. 2006;30(1-2):17-8.

PMID:
17192609
17.

Bromoenterobactins as potent inhibitors of a pathogen-associated, siderophore-modifying C-glycosyltransferase.

Lin H, Fischbach MA, Gatto GJ Jr, Liu DR, Walsh CT.

J Am Chem Soc. 2006 Jul 26;128(29):9324-5.

PMID:
16848455
18.

(E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa.

Spoettl T, Paetzel C, Herfarth H, Bencherif M, Schoelmerich J, Greinwald R, Gatto GJ, Rogler G.

Int J Colorectal Dis. 2007 Mar;22(3):303-12. Epub 2006 May 20.

PMID:
16715250
19.

Biosynthesis of pipecolic acid by RapL, a lysine cyclodeaminase encoded in the rapamycin gene cluster.

Gatto GJ Jr, Boyne MT 2nd, Kelleher NL, Walsh CT.

J Am Chem Soc. 2006 Mar 22;128(11):3838-47.

PMID:
16536560
20.

Protein posttranslational modifications: the chemistry of proteome diversifications.

Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr.

Angew Chem Int Ed Engl. 2005 Dec 1;44(45):7342-72. Review.

PMID:
16267872
21.

AknT is an activating protein for the glycosyltransferase AknS in L-aminodeoxysugar transfer to the aglycone of aclacinomycin A.

Lu W, Leimkuhler C, Gatto GJ Jr, Kruger RG, Oberthür M, Kahne D, Walsh CT.

Chem Biol. 2005 May;12(5):527-34.

22.

Elucidating the substrate specificity and condensation domain activity of FkbP, the FK520 pipecolate-incorporating enzyme.

Gatto GJ Jr, McLoughlin SM, Kelleher NL, Walsh CT.

Biochemistry. 2005 Apr 26;44(16):5993-6002.

PMID:
15835888
23.

Detecting patterns of protein distribution and gene expression in silico.

Bassett D, Morrell JC, Gatto GJ Jr, Bai J, Geisbrecht BV, Hieter P, Gould SJ.

Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):516. No abstract available.

24.

TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects.

Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, Reibaud M, Pradier L, Dunbar G, Bencherif M.

CNS Drug Rev. 2004 Summer;10(2):147-66. Review.

25.

Pex5p binding affinities for canonical and noncanonical PTS1 peptides.

Maynard EL, Gatto GJ Jr, Berg JM.

Proteins. 2004 Jun 1;55(4):856-61.

PMID:
15146484
26.

The design of functional DNA-binding proteins based on zinc finger domains.

Jantz D, Amann BT, Gatto GJ Jr, Berg JM.

Chem Rev. 2004 Feb;104(2):789-99. Review. No abstract available.

PMID:
14871141
27.

Nonrandom tripeptide sequence distributions at protein carboxyl termini.

Gatto GJ Jr, Berg JM.

Genome Res. 2003 Apr;13(4):617-23.

28.

Correlating structure and affinity for PEX5:PTS1 complexes.

Gatto GJ Jr, Maynard EL, Guerrerio AL, Geisbrecht BV, Gould SJ, Berg JM.

Biochemistry. 2003 Feb 18;42(6):1660-6.

PMID:
12578380
29.

The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.

Delaporte E, Slaughter DE, Egan MA, Gatto GJ, Santos A, Shelley J, Price E, Howells L, Dean DC, Rodrigues AD.

J Biomol Screen. 2001 Aug;6(4):225-31.

PMID:
11689122
30.

High-throughput simultaneous determination of the HIV protease inhibitors indinavir and L-756423 in human plasma using semi-automated 96-well solid phase extraction and LC-MS/MS.

Rose MJ, Merschman SA, Eisenhandler R, Woolf EJ, Yeh KC, Lin L, Fang W, Hsieh J, Braun MP, Gatto GJ, Matuszewski BK.

J Pharm Biomed Anal. 2000 Dec 15;24(2):291-305.

PMID:
11130208
31.

Peroxisomal targeting signal-1 recognition by the TPR domains of human PEX5.

Gatto GJ Jr, Geisbrecht BV, Gould SJ, Berg JM.

Nat Struct Biol. 2000 Dec;7(12):1091-5. Erratum in: Nat Struct Biol 2002 Oct;9(10):788.

PMID:
11101887
32.

TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors.

Bencherif M, Bane AJ, Miller CH, Dull GM, Gatto GJ.

Eur J Pharmacol. 2000 Dec 1;409(1):45-55.

PMID:
11099699
33.

A proposed model for the PEX5-peroxisomal targeting signal-1 recognition complex.

Gatto GJ Jr, Geisbrecht BV, Gould SJ, Berg JM.

Proteins. 2000 Feb 15;38(3):241-6.

PMID:
10713985
34.

Detecting patterns of protein distribution and gene expression in silico.

Geraghty MT, Bassett D, Morrell JC, Gatto GJ Jr, Bai J, Geisbrecht BV, Hieter P, Gould SJ.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2937-42. Retraction in: Bassett D, Morrell JC, Gatto GJ Jr, Bai J, Geisbrecht BV, Hieter P, Gould SJ. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):516.

35.
36.
37.
38.

The Nitric Oxide Synthase Inhibitor l-NAME (Nω-Nitro-L-Arginine Methyl Ester) Does Not Produce Discriminative Stimulus Effects Similar to Ethanol.

Green KL, Gatto GJ, Grant KA.

Alcohol Clin Exp Res. 1997 May;21(3):483-488. doi: 10.1111/j.1530-0277.1997.tb03794.x.

PMID:
28715102
40.

Metabolic mapping of the effects of chronic voluntary ethanol consumption in rats.

Williams-Hemby L, Grant KA, Gatto GJ, Porrino LJ.

Pharmacol Biochem Behav. 1996 Jun;54(2):415-23.

PMID:
8743604
41.
42.
43.

Ethanol self-infusion into the ventral tegmental area by alcohol-preferring rats.

Gatto GJ, McBride WJ, Murphy JM, Lumeng L, Li TK.

Alcohol. 1994 Nov-Dec;11(6):557-64.

PMID:
7865158
44.

Comparison of alcohol-preferring (P) and nonpreferring (NP) rats on tests of anxiety and for the anxiolytic effects of ethanol.

Stewart RB, Gatto GJ, Lumeng L, Li TK, Murphy JM.

Alcohol. 1993 Jan-Feb;10(1):1-10.

PMID:
8095393
45.

CNS mechanisms of alcohol self-administration.

McBride WJ, Murphy JM, Gatto GJ, Levy AD, Yoshimoto K, Lumeng L, Li TK.

Alcohol Alcohol Suppl. 1993;2:463-7.

PMID:
7748340
46.

The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices.

Stearns RA, Miller RR, Doss GA, Chakravarty PK, Rosegay A, Gatto GJ, Chiu SH.

Drug Metab Dispos. 1992 Mar-Apr;20(2):281-7.

PMID:
1352222
47.

Serotonin and dopamine systems regulating alcohol intake.

McBride WJ, Murphy JM, Gatto GJ, Levy AD, Lumeng L, Li TK.

Alcohol Alcohol Suppl. 1991;1:411-6.

PMID:
1726986
48.

Effects of fluoxetine and desipramine on palatability-induced ethanol consumption in the alcohol-nonpreferring (NP) line of rats.

Gatto GJ, Murphy JM, McBride WJ, Lumeng L, Li TK.

Alcohol. 1990 Nov-Dec;7(6):531-6.

PMID:
2261092
49.

Persistence of tolerance in the P line of alcohol-preferring rats does not require performance while intoxicated.

Murphy JM, Gatto GJ, McBride WJ, Lumeng L, Li TK.

Alcohol. 1990 Jul-Aug;7(4):367-9.

PMID:
2390212
50.

Operant responding for oral ethanol in the alcohol-preferring P and alcohol-nonpreferring NP lines of rats.

Murphy JM, Gatto GJ, McBride WJ, Lumeng L, Li TK.

Alcohol. 1989 Mar-Apr;6(2):127-31.

PMID:
2713085

Supplemental Content

Loading ...
Support Center